CH573435A5 - - Google Patents

Info

Publication number
CH573435A5
CH573435A5 CH955873A CH955873A CH573435A5 CH 573435 A5 CH573435 A5 CH 573435A5 CH 955873 A CH955873 A CH 955873A CH 955873 A CH955873 A CH 955873A CH 573435 A5 CH573435 A5 CH 573435A5
Authority
CH
Switzerland
Application number
CH955873A
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CH573435A5 publication Critical patent/CH573435A5/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CH955873A 1972-07-01 1973-06-29 CH573435A5 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6630172A JPS5512435B2 (cg-RX-API-DMAC10.html) 1972-07-01 1972-07-01

Publications (1)

Publication Number Publication Date
CH573435A5 true CH573435A5 (cg-RX-API-DMAC10.html) 1976-03-15

Family

ID=13311838

Family Applications (1)

Application Number Title Priority Date Filing Date
CH955873A CH573435A5 (cg-RX-API-DMAC10.html) 1972-07-01 1973-06-29

Country Status (15)

Country Link
US (1) US3925357A (cg-RX-API-DMAC10.html)
JP (1) JPS5512435B2 (cg-RX-API-DMAC10.html)
AT (1) AT325206B (cg-RX-API-DMAC10.html)
AU (1) AU469986B2 (cg-RX-API-DMAC10.html)
BE (1) BE801588A (cg-RX-API-DMAC10.html)
CA (1) CA996548A (cg-RX-API-DMAC10.html)
CH (1) CH573435A5 (cg-RX-API-DMAC10.html)
CS (1) CS168036B2 (cg-RX-API-DMAC10.html)
DE (1) DE2332840A1 (cg-RX-API-DMAC10.html)
FR (1) FR2190414B1 (cg-RX-API-DMAC10.html)
GB (1) GB1386566A (cg-RX-API-DMAC10.html)
HU (1) HU166029B (cg-RX-API-DMAC10.html)
NL (1) NL7308048A (cg-RX-API-DMAC10.html)
PL (1) PL92969B1 (cg-RX-API-DMAC10.html)
SE (1) SE402916B (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522148U (cg-RX-API-DMAC10.html) * 1978-07-29 1980-02-13
EE05735B1 (et) * 2001-02-24 2015-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
US20030171424A1 (en) * 2002-03-07 2003-09-11 Lin Ai J. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
PE20091730A1 (es) * 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101657960B1 (ko) * 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Fab-관련 질환의 치료에 사용하기 위한 푸린 유도체
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1026793A (fr) * 1949-08-02 1953-05-04 American Cyanamid Co Procédé de préparation de sels de pénicilline
NL6803062A (cg-RX-API-DMAC10.html) * 1967-03-10 1968-09-11
US3557094A (en) * 1968-01-05 1971-01-19 Pfizer & Co C Substituted alkyl esters of alpha-carboxy aryl penicillins
AT290728B (de) * 1968-09-28 1971-05-15 Takeda Chemical Industries Ltd Verfahren zur herstellung neuer penicilline

Also Published As

Publication number Publication date
CA996548A (en) 1976-09-07
DE2332840A1 (de) 1974-01-17
CS168036B2 (cg-RX-API-DMAC10.html) 1976-05-28
FR2190414A1 (cg-RX-API-DMAC10.html) 1974-02-01
HU166029B (cg-RX-API-DMAC10.html) 1974-12-28
US3925357A (en) 1975-12-09
AU5760073A (en) 1975-01-09
PL92969B1 (cg-RX-API-DMAC10.html) 1977-04-30
GB1386566A (en) 1975-03-12
JPS5512435B2 (cg-RX-API-DMAC10.html) 1980-04-02
NL7308048A (cg-RX-API-DMAC10.html) 1974-01-03
BE801588A (fr) 1973-12-28
FR2190414B1 (cg-RX-API-DMAC10.html) 1976-07-02
AU469986B2 (en) 1976-02-26
AT325206B (de) 1975-10-10
SE402916B (sv) 1978-07-24
JPS4925121A (cg-RX-API-DMAC10.html) 1974-03-06

Similar Documents

Publication Publication Date Title
FR2190414B1 (cg-RX-API-DMAC10.html)
FR2172216A1 (cg-RX-API-DMAC10.html)
JPS5222978Y2 (cg-RX-API-DMAC10.html)
FR2186058A5 (cg-RX-API-DMAC10.html)
JPS537930Y2 (cg-RX-API-DMAC10.html)
JPS5147151Y2 (cg-RX-API-DMAC10.html)
JPS5318575B2 (cg-RX-API-DMAC10.html)
JPS4964331U (cg-RX-API-DMAC10.html)
JPS5028233Y2 (cg-RX-API-DMAC10.html)
JPS531429Y2 (cg-RX-API-DMAC10.html)
JPS5215025Y2 (cg-RX-API-DMAC10.html)
JPS4983044U (cg-RX-API-DMAC10.html)
JPS4897175U (cg-RX-API-DMAC10.html)
JPS4983820A (cg-RX-API-DMAC10.html)
JPS499092U (cg-RX-API-DMAC10.html)
CH587225A5 (cg-RX-API-DMAC10.html)
CH584708A5 (cg-RX-API-DMAC10.html)
CH569399A5 (cg-RX-API-DMAC10.html)
SE7206708L (cg-RX-API-DMAC10.html)
SE7010788L (cg-RX-API-DMAC10.html)
CH573257A5 (cg-RX-API-DMAC10.html)
CH591554A5 (cg-RX-API-DMAC10.html)
CH590921A5 (cg-RX-API-DMAC10.html)
CH590264A5 (cg-RX-API-DMAC10.html)
CH588510A5 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
PL Patent ceased
PL Patent ceased